Information de reference pour ce titreAccession Number: | 00002953-200002000-00015.
|
Author: | De Vita, Ferdinando MD, PhD; Orditura, Michele MD; Galizia, Gennaro MD; Romano, Ciro MD, PhD; Roscigno, Annarita MD; Lieto, Eva MD; Catalano, Giuseppe MD, PhD
|
Institution: | *From the Department of Clinical & Experimental Medicine "F. Magrassi," Second University of Naples School of Medicine, Naples, Italy
|
Title: | Serum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients*.[Article]
|
Source: | Chest. 117(2):365-373, February 2000.
|
Abstract: | Study objective: To investigate the prognostic significance of interleukin (IL)-10 serum levels in advanced non-small cell lung cancer (NSCLC) patients.
Design: IL-10 serum levels were measured before chemotherapy, on completion of therapy, and at follow-up by means of a commercially available enzyme-linked immunoassay. The results were then analyzed in comparison with other prognostic variables, and a model predicting overall survival (OS) and time to treatment failure (TTF) was finally generated.
Setting: University hospital.
Patients: Sixty consecutive patients with TNM stage III or IV NSCLC undergoing conventional platinum-based regimens.
Results: Elevated levels of serum IL-10 were found in cancer patients with respect to healthy control subjects (17.7 +/- 4.4 vs 9.2 +/- 1.5 pg/mL, respectively; p < 0.05), with patients with metastatic disease showing significantly higher levels than patients with undisseminated cancer (21.0 +/- 4.2 vs 14.3 +/- 1.2 pg/mL, respectively; p < 0.05). Following completion of treatment, patients were classified as responders if they had achieved either one of the following: complete response, partial response, or stable disease; and nonresponders, in case of progressive disease. Retrospective analysis of basal IL-10 serum levels in these two subgroups showed a significant difference between responders and nonresponders (15.2 +/- 2.2 vs 21.4 +/- 4.2 pg/mL, respectively; p < 0.05). Moreover, a further significant increase in IL-10 serum levels was observed in nonresponders at the end of therapy (21.4 +/- 4.2 vs 26.0 +/- 4.3 pg/mL, prechemotherapy and postchemotherapy, respectively; p < 0.05), whereas values in responders were found to have significantly decreased (15.2 +/- 2.2 vs 14.8 +/- 2.2 pg/mL, prechemotherapy and postchemotherapy, respectively; p < 0.05). Using univariate and multivariate analyses, both OS and TTF were shown to be affected by the mean pathologic levels of IL-10. Stepwise regression analysis identified IL-10 serum level and stage as the prognostic factors related to OS, and IL-10 serum level and performance status as the prognostic factors related to TTF.
Conclusions: In conclusion, this study shows that the measurement of pretreatment IL-10 serum levels is of independent prognostic utility in patients with NSCLC and may be useful for detection of disease progression.
(C) 2000Elsevier, Inc.
|
Author Keywords: | interleukin-10 serum levels; non-small cell lung cancer; prognosis.
|
References: | 1 Hellstrom KE, Hellstrom I, Brown JP. Unique and common tumor-specific transplantation antigens of chemically-induced mouse sarcomas. Int J Cancer 1978; 21:317-322
2 Lynch DH, Miller RE. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice. Eur J Immunol 1991; 21:1403-1410
3 Barsoum AL, Coggin JH. Immunogenicity of a soluble partially purified oncofetal antigen from murine fibrosarcoma in syngeneic mice. J Biol Response Mod 1989; 8:579-592
4 Pawelec G, Zeuthen J, Kiessling R. Escape from host-antitumor immunity. Crit Rev Oncog 1997; 8:111-141
5 Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993; 60:247-267
6 Chouaib S, Assclin Paturel C, Mami Chouaib F, et al. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18:493-497
7 Oppenheim J, Fujiwara H. The role of cytokines in cancer. Cytokine Growth Factor Rev 1996; 7:279-288
8 Venetsanakos E, Beckman I, Bradley J, et al. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer 1997; 75:1826-1830
9 Morisaki T, Katano M, Ikubo A, et al. Immunosuppressive cytokines (IL-10, TGF-beta) genes expression in human gastric carcinoma tissues. J Surg Oncol 1996; 63:234-239
10 Spellman JE. Gollnick SO, Zhang PJ, et al. Cytokine production by human soft tissue sarcomas: implications for immunosuppression within the tumour bed. Surg Oncol 1996; 5:237-244
11 Romagnani S. Lymphokine production by human T cells in disease states. Ann Rev Immunol 1994; 12:227-257
12 Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Ann Rev Immunol 1993; 11:165-190
13 de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-924
14 Kazuyuki T, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T cell growth. Blood 1993; 81:2964-2971
15 Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996; 56:5499-5505
16 Gotlieb WH, Abrams J, Watson JM, et al. Presence of interleukin (IL)-10 in the ascites of patients with ovarian and other intra-abdominal cancer. Cytokine 1992; 4:385-390
17 Dummer W, Bastian BC, Ernst N, et al. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996; 66:607-610
18 Gastl GA, Abrams JS, Nanus DM, et al. Interleukin-10 production by by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993; 55:96-101
19 Smith DR, Kunkel SL, Burdick MD, et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994; 145:18-25
20 Huang M, Wang J, Lee P, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995; 55:3847-3853
21 Blay JY, Burdin N, Rousset F, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993; 82:2169-2174
22 Wojciechowska Lacka A, Matecka Nowak M, Adamiak E, et al. Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer. Neoplasma 1996; 43:155-158
23 Fortis C, Foppoli M, Gianotti L, et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 1996; 104:1-5
24 Garfinkel A. Cancer statistics and trends. In: Holleb AI, Fink DJ, Murphy GP, eds. American Cancer Society textbook of clinical oncology. Atlanta, GA: American Cancer Society, 1991; 2-9
25 Dubinett SM, Kradin RL. Cytokine immunotherapy of non-small cell lung cancer. Reg Immunol 1993; 5:232-242
26 Ralph P, Nakoinz I, Sampson-Johannes A, et al. IL-10, T-lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992; 148:808-814
27 Spagnoli GC, Juretic A, Schultz-Thater E, et al. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity. Cell Immunol 1993; 146:391-405
28 Avradopoulos K, Mehta S, Blackinton D, et al. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann Surg Oncol 1997; 4:184-190
29 Gianotti L, Fortis C, Braga M, et al. Radical oncologic surgery affects the circulatory levels of interleukin 10. J Surg Oncol 1997; 66:244-247
|
Language: | English.
|
Document Type: | Clinical Investigations: Lung Cancer.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0012-3692
|
NLM Journal Code: | 0231335, d1c
|
Annotation(s) | |
|
|